← Shelf·GIP + GLP-1 dual agonist·VIII.
Tirzepatide.
A 39-residue synthetic linear peptide engineered as a dual receptor agonist at both the GIP receptor and the GLP-1 receptor. Developed by Eli Lilly; the dual incretin-receptor agonist researchers reference by this name.
Two of your gut's own incretin hormones — GIP and GLP-1 — engage separate receptors on the pancreatic beta cell after you eat. Tirzepatide engineers both signals into a single molecule with an extended plasma half-life.
The 'stronger cousin of semaglutide' story dominates the internet. What the story rarely covers is the receptor pharmacology that makes tirzepatide interesting to endocrinologists in the first place — that's in the primary literature, not the marketing.
Straight talk
Straight talk: the receptor pharmacology is real and heavily published in the Lilly SURPASS trial series. Whether the research-grade compound in a given vial IS the same molecule as the FDA-approved drug of the same INN is exactly what a third-party COA is for. Buy on documentation, not on brand adjacency.
What the research studies
The literature, not a summary of it.
The core clinical record is Eli Lilly's SURPASS trial series (Frías, Rosenstock, Del Prato, Coskun and colleagues) published across NEJM, Lancet, Diabetes Care, JAMA. Upstream incretin receptor pharmacology is Drucker/Nauck/Holst lineage. Read the research yourself:
Recommended vendor · Amino Club
≥ 99% by HPLC on the current lot — ILS Laboratories (ISO/IEC 17025). Sold by Amino Club as GLP-2 (TR); the coded product name is the vendor's, the INN is ours for reference.
$38.99 during Fall Sale (was $59.99, 30MG)
35% off applied automatically at checkout when you land through this link.